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ABSTRACT
Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain
Molly S. Crowe
Neuropathic pain is caused by altered nerve function that often presents as allodynia, which is
the painful perception of typically non-noxious stimuli. Neuropathic pain is commonly treated
with GABA analogues, steroids, or non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs
inhibit one or more cyclooxygenase (COX) enzymes and are effective, commonly used
analgesics that have relatively fewer side effects than other treatments. However, chronic
cyclooxygenase inhibition also causes gastrointestinal inflammation and increased risk of cardiac
events. Like NSAIDs, cannabinoids have analgesic and anti-inflammatory properties and reduce
neuropathic pain in preclinical models. The present study investigated the analgesic effects of
inhibiting both monoacylglycerol lipase (MAGL) and cyclooxygenase enzymes. Mice subjected
to the chronic constriction injury (CCI) model of neuropathic pain were administered either the
MAGL inhibitor, JZL184 (1-40 mg/kg, i.p.) or the nonselective COX inhibitor diclofenac
sodium (1-100 mg/kg, i.p.) and tested for mechanical and cold allodynia. Then, both drugs were
coadministered at various doses in ratios of 1:3, 1:1, and 3:1 parts of either compound.
Isobolographic analyses revealed that combining low doses of JZL184 and diclofenac
synergistically attenuated mechanical allodynia and additively reduced cold allodynia. These
data support dual COX/MAGL inhibition as a promising therapeutic approach for neuropathic
pain.
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Background
Neuropathic Pain
Pain (i.e., nociception) has evolved to functionally serve as a warning sign of tissue
damage or imminent threat of tissue damage to an individual. Pain can be broadly classified as
either adaptive or maladaptive. Adaptive pain is produced by exceeding a noxious stimulus
threshold, for example, by placing one’s hand into an open flame. However, maladaptive forms
of pain can develop when an injury remains unresolved, for example in the case of chronic
inflammatory pain, or in cases where the pain circuits themselves are altered, as occurs with
neuropathic pain.
Neuropathic pain is caused by a broad range of insults including peripheral nerve injury,
autoimmune and other disease states, or toxic insult (Rahn & Hohmann, 2009; Scholz & Woolf,
2002; Zimmermann, 2001). In contrast to acute adaptive pain, neuropathic pain develops over a
relatively long time and presents most commonly as spontaneous pain, hypersensitivity to
noxious stimuli (i.e., hyperalgesia), or pain perception to non-noxious stimuli (i.e., allodynia).
Because pain is vital for survival, the goal of any therapeutic approach is to reduce nociception
to a manageable level, but not to eliminate the ability to feel any pain (i.e., antinociception).
Neuropathic pain decreases quality of life and is comorbid with decreased physical and
emotional functioning, including depression, anxiety, sleep disturbances, social withdrawal, and
physical constraints (Jensen, Chodroff, & Dworkin, 2007; Sofaer-Bennett et al., 2007). Chronic
pain conditions are associated with suicidal ideation which can be exacerbated by psychological
comorbidities (Braden & Sullivan, 2008). These interactions between physical and psychological
pain highlight the need to develop new treatments for both pain and its associated emotional side
effects. Moreover, the psychological comorbidities elicited by chronic pain do not only affect the
patient but the people surrounding the individual as well. Relationships can become strained due
to the stressful nature of dealing with such a chronic affliction, as well as the aforementioned,
associated emotional side effects (Sofaer-Bennett et al., 2007).
Although the emotional burden that neuropathic pain imposes on afflicted individuals and
their caregivers is immeasurable, the economic burden of pain is somewhat easier to account for.
These costs include the direct costs of medical care as well as indirect costs such as loss of
productivity, disability, and decrease in work hours. Just in the United States, these costs are
estimated to total around $560-630 billion per year (IOM, 2011). In addition to this strain on the
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U.S. economy, an estimated $2.6 billion is spent on non-prescription analgesics including a class
of enzyme inhibitors known broadly as non-steroidal anti-inflammatory drugs (NSAIDs)
(Krueger & Stone, 2008).
Current Pain Treatments
Neuropathic pain is difficult to treat and is often refractory to current pain treatments,
including conventional analgesic medications. Given the well-documented side effects of
traditional analgesics such as opioids, NSAIDs remain the most commonly used analgesics for
neuropathic pain (although many other forms of chronic pain are also resistant to NSAIDs).
Acetylsalicylic acid (aspirin) is the prototypical NSAID and has been used in humans for over
100 years (Lanas, 2009). Aspirin is used worldwide as an inexpensive analgesic and cardioprotective agent (Lanas, 2009). Currently, there are manifold NSAID treatments including
diclofenac sodium, ibuprofen, and naproxen (Lanas, 2009; Patrono & Baigent, 2009). The
availability of numerous NSAIDs having the same mechanism of action suggests high
pharmacokinetic variability among drugs and an inconsistency in effective treatment (Patrono &
Baigent, 2009).
Notably, the side effects of NSAIDs are less severe than many other pain treatments, such
as opioids. As effective as NSAIDs may be as analgesics, chronic NSAID use may cause severe
gastrointestinal bleeding side effects, which are potentially life-threatening, especially in the
elderly, who are also more likely to use NSAIDs regularly for a range of chronic pain and/or
inflammatory conditions (Musumba, Pritchard, & Pirmohamed, 2009).
NSAIDs decrease pain and inflammation by inhibiting cyclooxygenase (COX-1 and
COX-2) enzyme activity, subsequently blocking prostaglandin synthesis. Prostaglandins are
lipids that are produced throughout the body and modulate physiological processes including
inflammation. Prostaglandins in the GI tract regulate and maintain gastric mucosa and gastric
acid secretions (Singh, 1998). COX-1 is constitutively produced, provides homeostatic functions,
and regulates the gastric mucosa (Rouzer & Marnett, 2009), while COX-2 is induced by tissue
injury and is involved in regulating inflammation (Viegas, Manso, Corvo, Marques, & Cabrita,
2011). Although inhibiting COX-1 has acute anti-inflammatory effects, it paradoxically causes
GI inflammation by altering regulatory prostaglandins levels. For example, causing gastric
hemorrhages by one or more mechanisms can result in hindered gastric endothelial cell renewal
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and delayed healing of the stomach (Musumba et al., 2009). The severity of side effects increases
with age and can be predicted to some degree by the patient’s medical history (Raffa, 2001).
In order to circumvent the GI side effects caused by nonselective COX inhibitors, highly
selective cyclooxygenase-2 isozyme inhibitors called coxibs were developed over 10 years ago.
Although coxibs potently reduced pain and inflammation without GI side effects in humans
(FitzGerald & Patrono, 2001), they also increased the risk of major vascular complications,
especially heart attacks (Patrono & Baigent, 2009). Coxibs remain on the market, however the
controversy sparked by these COX-2 selective enzyme inhibitors has weakened enthusiasm for
their widespread use.
In addition to NSAIDs, other classes of drugs used to treat neuropathic pain include
opioids, antidepressants, and antiepileptics. Opioids, including morphine, methadone, and
oxycodone, have analgesic effects that persist through long-term treatment (~28 days), whereas
short-term trials (less than eight hours) produce mixed results in humans (Eisenberg, McNicol, &
Carr, 2006). Opioids also have well-characterized side effects that do not attenuate after repeated
administration. Patients treated with opioids may experience nausea, constipation, dizziness,
drowsiness, or vomiting (Eisenberg et al., 2006). Opioids are also accompanied with a high
potential for abuse and drug dependence, lessening their appeal for routine use. Moderate
analgesic effects of the anti-depressant serotonin-noradrenaline reuptake inhibitors (SNRIs) have
been documented, whereas selective serotonin reuptake inhibitors (SSRIs) are inadequate for
pain relief (Attal et al., 2006). The most effective antiepileptics for neuropathy are gabapentin (a
gamma-Aminobutyric acid (GABA) analogue) and pregabalin (Attal et al., 2006). However,
these drugs also have adverse side effects including drowsiness, dizziness, and ataxia (Beal,
Moeller-Bertram, Schilling, & Wallace, 2012).
Given the intractable nature of neuropathic pain and the previously mentioned side
effects of current treatments, some patients self-medicate with drugs of abuse, including
Cannabis. Cannabis has been used for at least four thousand years to treat many medical and
emotional conditions, including pain (Mechoulam & Parker, 2012). In humans, Cannabis
attenuates a multitude of disease symptoms including those of cancer, multiple sclerosis,
neurodegenerative diseases, and other chronic pain states (Kogan & Mechoulam, 2007). Human
immunodeficiency virus (HIV) patients have reported benefiting from Cannabis in appetite,
muscle pain, nausea, anxiety, neuropathic pain, depression, and paresthesia (Woolridge et al.,
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2005). Since the primary psychoactive constituent of Cannabis, ∆9-tetrahydrocannabinol (THC),
was first identified nearly 50 years ago (Gaoni & Mechoulam, 1964) many other cannabinoids
have been identified and cloned. Cannabinoids inhibit neuronal transmission in pain pathways,
thereby reducing pain (Kogan & Mechoulam, 2007). Because of its antiemetic and prophagic
effects, a synthetic, oral preparation of THC, dronabinol, is currently approved by the Food and
Drug Administration for the treatment of chronic wasting conditions.
As with opioids, although there are advantages to using Cannabis as an analgesic
treatment, there are considerable concerns about dependence and psychomimetic effects.
Cannabis can cause unwanted behavioral and cognitive effects. These consist of attention,
memory, and motor deficits, but can also increase the risk of schizophrenia-like psychoses
(Kogan & Mechoulam, 2007). To avoid these negative side effects, and also to better understand
the biological mechanisms involved in the many processes that cannabinoids affect, current
research focuses on the endogenous cannabinoid (i.e., endocannabinoid; eCB) system. The
endocannabinoid system is involved in many neurobehavioral processes, including pain,
inflammation, learning, memory, energy, and feeding regulation (Lichtman, Blankman, &
Cravatt, 2010).
Endocannabinoid System
Two eCB receptor subtypes have been identified and cloned, cannabinoid receptor 1
(CB1) and cannabinoid receptor 2 (CB2). CB1 is expressed throughout the body and is implicated
in the neurobiological effects of cannabinoid agonists, including hypothermia, immobility, and
cognitive deficits (Herkenham et al., 1991). Selective CB1 receptor antagonists block the
psychoactive effects of THC (Wise, Thorpe, & Lichtman, 2009). CB2 receptors are expressed
predominately on immune cells but have recently been identified in the central nervous system,
particularly in the brain stem and on microglia, which function as immune cells of the nervous
system (Mechoulam & Parker, 2012). The two endogenous cannabinoids, Narachidonylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), bind to and
activate both cannabinoid receptors (Ahn, McKinney, & Cravatt, 2008). Brain levels of 2-AG are
approximately 200-fold higher than anandamide levels (Kinsey et al., 2011). Oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA) are also considered endocannabinoids, however they
have low affinity for CB1 and CB2 receptors, and bind only at very high concentrations in vitro
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(Lambert et al., 1999; Sheskin, Hanus, Slager, Vogel, & Mechoulam, 1997), thus casting doubt
on their physiological relevance.
An interesting characteristic of endocannabinoids is that, unlike most neurotransmitters,
endocannabinoids are retrograde messengers. For example, 2-AG is synthesized in the
postsynaptic neuron, from which it travels backwards across the synapse and binds with the
receptor on the presynaptic neuron (Mechoulam & Parker, 2012). Although some controversy
exists over whether anandamide acts in the same retrograde way, this retrograde transmission
parallels the general inhibitory effects of eCBs in neural networks. Another unusual
characteristic of endocannabinoids as neurotransmitters is that they are synthesized on demand
and are not stored in vesicles in the axon terminus, due to their lipophilic nature (Mechoulam &
Parker, 2012).
Endocannabinoid levels are tightly regulated in vivo by synthetic and metabolic enzymes.
Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) regulate anandamide
and 2-AG, respectively. These enzymes metabolize their target endocannabinoids, resulting in
shortened activity. Arachidonic acid is a metabolite of both anandamide (with ethanolamine) and
2-AG (with glycerol). Exogenous administration of the endocannabinoids is therapeutically
ineffective due to the rapid degradation by FAAH and MAGL in vivo. However, the genetic
deletion or pharmacological inhibition of MAGL or FAAH increases brain levels of 2-AG or
anandamide causing analgesia (Kinsey et al., 2009; Lichtman, Shelton, Advani, & Cravatt, 2004;
Long et al., 2009).
Neuropathic Pain Model
Animal models of neuropathic pain are used to better understand the neurobiological
etiology of the disease states as well as possible therapeutic treatments. The best characterized
mouse model of neuropathic pain uses partial ligation of the sciatic nerve, and is known as
chronic constriction injury (CCI). After the nerve ligation, immune cells at the injury site and
glia in the dorsal root ganglia of the spinal cord located ipsilateral to the injury produce
proinflammatory cytokines, which then activate other immune cells to permeate the injured area
(McMahon, Cafferty, & Marchand, 2005). The inflammatory response initiated by CCI causes
mechanical and cold allodynia in the paw that is ipsilateral to the nerve injury, while the paw that
is contralateral to the injury is unaffected by the surgery (Table 1) and may be used as a control,
thus reducing the number of animals required in this model. In experimental animal models of
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pain, allodynia is operationally defined by various behavioral responses to paw stimulation that
involve the mouse lifting its paw off the testing table. Similarly, patients suffering from
neuropathic pain report an increase in touch and cold sensitivity, thus increasing the clinical
relevance of CCI as an experimental animal model of neuropathic pain (Attal et al., 2006). CB1
receptor expression in the spinal cord increases after CCI surgery in rats (Lim, Sung, Ji, & Mao,
2003), further demonstrating pain modulation by eCB is a promising treatment of pain
perception behaviors.
As mentioned above, manipulation of endocannabinoids in vivo is possible via selective
inhibition of endocannabinoid metabolic enzymes. For example, PF-3845 and JZL184 are
pharmacological compounds that inhibit FAAH and MAGL, respectively (Figure 1). FAAH or
MAGL inhibition prevents the breakdown of anandamide or 2-AG, which leads to increased
brain levels of either eCB, resulting in cannabinoid receptor mediated analgesia. Administration
of either compound decreases mechanical and cold allodynia in mice (Kinsey et al., 2009;
Kinsey, O’Neal, Long, Cravatt, & Lichtman, 2011). FAAH or MAGL inhibition significantly
attenuates mechanical and cold allodynia in the CCI model (i.e., decreasing paw lifting) in mice.
Unlike the exogenous cannabinoid THC, JZL184 and PF-3845 have no effect on locomotor
activity, indicating that their analgesic effects are not due to sedation (Kinsey, O'Neal, et al.,
2011). CB1 and CB2 antagonists reverse the anti-allodynic effects of FAAH inhibitors in the CCI
model (Kinsey et al., 2009; La Rana et al., 2008; Russo et al., 2007). Conversely, the antiallodynic effects of JZL184 were only blocked by the CB1 antagonist rimonabant (SR141716A),
indicating that MAGL inhibition reduces neuropathic pain via a mechanism involving CB1, but
not CB2, receptors (Kinsey et al., 2009). JZL184 also increases brain level of 2-AG after oral
administration in mice (Long et al., 2009), increasing the clinical applicability of MAGL
inhibition as a potential therapeutic target.
In contrast to opioids, non-human primates do not self-administer the FAAH inhibiter
URB597, indicating that inhibition of endocannabinoid enzymes is a feasible therapeutic option
for attenuating pain, with reduced abuse potential (Justinova et al., 2008).
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Analgesic Additivity and Synergy
Combining drugs with different mechanisms of action can produce greater pain
attenuation than individually administered analgesics (Raffa, 2001). This dual administration
approach may allow for subclinical dose of each drug, thereby lessening the side effects of each
compound while maintaining adequate pain relief (Guindon, Walczak, & Beaulieu, 2007). This
type of broader coverage of multiple mechanisms is used successfully in the treatment of
diseases such as HIV, diabetes, and hypertension, and, thus, pair dosing may also be effective for
neuropathic pain treatments (Raffa, 2001; Tallarida, 2011).
Pair dosing of drugs with similar experimental outcomes can produce results that are less
than (subadditive), equal to (additive) or greater than (synergistic) individual effectiveness of
either compound (Tallarida, 2011). For example, a subadditive drug interaction would have an
antagonistic effect, resulting in lower expected effects than either drug when administered alone.
On the other hand, an additive drug interaction is when dual administration results in an effect
that is very similar or equal to the sum of the expected effects of each of the individual drugs
when administered alone. Finally, a drug interaction is considered to be synergistic when the
result of the amalgamation is above the singular expected efficacy of the sum of the effects of
each drug.
When looking for synergism, each drug must have similar individual potency in order to
contribute to the combined effects (Tallarida, 2011). Endocannabinoid enzyme inhibitors and
NSAIDs attenuate allodynia via distinct physiological mechanisms. As detailed above, NSAIDs
block prostaglandin synthesis by inhibiting COX-1 and/or COX-2, whereas JZL184 selectively
inhibits MAGL, thus increasing the endocannabinoid 2-AG, which binds to CB1 receptors.
Unpublished, preliminary data from our lab show the nonselective COX inhibitor diclofenac
partially attenuates mechanical and cold allodynia in mice subjected to CCI. Kinsey and
colleagues (2009) demonstrated that the MAGL inhibitor JZL184 attenuates mechanical and
acetone-induced cold allodynia. For the present study, these results were replicated and
extended, testing the anti-allodynic effects of a range of doses of JZL184 and diclofenac in mice
subjected to CCI. Therefore, COX and endocannabinoid modulators are viable candidates for
testing synergistic effects.
While reducing pain via separate mechanisms, eCB enzyme inhibitors and NSAIDs do
have a potential common pathway that may contribute to their potential synergistic analgesia:
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arachidonic acid. Arachidonic acid is a precursor for prostaglandin synthesis. FAAH and MAGL
inhibitors both block the breakdown of endocannabinoids into arachidonic acid, and NSAIDs
obstruct COX from synthesizing prostaglandins from arachidonic acid (Rouzer & Marnett,
2009). When given together, NSAIDs and MAGL inhibitors could work congruently to have an
enhanced effect over the standard monoadministration (Nomura et al., 2011). There is evidence
for such synergy. Indeed, at high doses, COX inhibitors also inhibit FAAH, thereby blocking the
metabolism of the exogenous anandamide resulting in reduced pain responses (Guindon &
Beaulieu, 2006), although this is not the primary mechanism through which COX inhibitors
attenuate pain.
Previous research has evaluated synergy in dual administration of NSAIDs and
anandamide modulators. Coadministration of the NSAID diclofenac and the FAAH inhibitor
URB597 in equipotent low doses synergistically attenuated acute visceral pain, which was
measured by number of stretching responses elicited by the intraperitoneal injection of dilute
acetic acid (Naidu, Booker, Cravatt, & Lichtman, 2009). Combined administration of diclofenac
and URB597 synergistically reduced the number of stretches. Local administration of exogenous
anandamide combined with a COX inhibitor (COX-2 selective, as well as non-selective COX
inhibitors were used), reduced thermal hyperalgesia and mechanical allodynia induced by partial
sciatic nerve ligation in rats (Guindon & Beaulieu, 2006). Another potent FAAH inhibitor,
URB937, was combined with the NSAID diclofenac sodium to synergistically reduce
mechanical and thermal hyperalgesia and mechanical allodynia in models of inflammatory and
neuropathic pain (Sasso et al., 2012). Subclinical doses of these drugs interacted synergistically
to significantly decrease pain responses in all three models of pain. Taken together, these studies
comparing COX and FAAH inhibitors support the idea of potential synergy between an NSAID
and a MAGL inhibitor to reduce the observed paw lifts in mice.
The present study was designed to investigate the possible synergy between the MAGL
inhibitor JZL184 and the COX inhibitor diclofenac sodium. This study sought to determine
whether the synergistic effects of endocannabinoid and COX modulation extend beyond acute
visceral and local pain models, as have been previously demonstrated. In addition, this study
extended previous findings by focusing on the MAGL inhibitor JZL184, instead of more
extensively studied FAAH inhibitors. The commonly prescribed NSAID diclofenac sodium, a
non-selective COX inhibitor, was used. It was hypothesized that coadministration of diclofenac
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sodium and JZL184 enhances the analgesic effects of either compound, reducing mechanical and
cold allodynia in the CCI mouse model of neuropathic pain.
Statement of the Problem
Neuropathic pain is a chronic ailment that decreases quality of life and correlates with
psychological disorders such as depression and anxiety (Jensen et al., 2007; Sofaer-Bennett et
al., 2007). Because neuropathic pain is particularly resistant to traditional analgesic treatments,
including COX enzyme inhibitors commonly known as non-steroidal anti-inflammatory drugs
(NSAIDs), patients often self-medicate with drugs of abuse, including Cannabis (Kogan &
Mechoulam, 2007). Traditional pain treatments including NSAIDs have negative and often
severe side effects, there is a pressing need to identify new targets and treatments for neuropathic
pain (Musumba et al., 2009). Current research focuses on the endogenous cannabinoid system,
due to its ability to elicit behavioral and physiological modifications without apparent
psychogenic side effects (Schlosburg, Kinsey, & Lichtman, 2009). Highly selective
endocannabinoid (eCB) enzyme inhibitors, which increase levels of eCBs in the brain and other
target tissues, attenuate hyperalgesia and allodynia caused by nerve injury (Kinsey et al., 2009;
Sasso et al., 2012).
Published reports support new therapeutic treatments that target both cyclooxygenase and
endocannabinoid metabolic enzymes. Synergy allows for the use of subclinical doses of each
compound, causing fewer side effects while maintaining analgesia (Guindon et al., 2007; Raffa,
2001). In addition, dual administration of an endocannabinoid enzyme inhibitor and an NSAID
synergistically reduce acute visceral and local pain (Guindon & Beaulieu, 2006; Naidu et al.,
2009).
To date, investigations of synergy between the endocannabinoid enzyme inhibitors and
COX inhibitors (i.e., NSAIDs) have focused entirely on fatty acid amide hydrolase (FAAH).
Thus, the NSAID diclofenac sodium and an eCB enzyme monoacylglycerol lipase (MAGL)
inhibitor were used to evaluate possible synergistic interactions in a neuropathic pain model.
Methods
Animals. Subjects consisted of 40 male C57BL/6J mice (Jackson Laboratory, Bar
Harbor, ME) that were approximately 20 weeks old at the start of the experiment. Mice were
housed 2-5 per cage in a temperature (20-22°C) and humidity controlled environment with ad
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libitum access to food and water. The Animal Care and Use Committee at West Virginia
University approved all experimental protocols (11-0903).
Chronic constriction injury (CCI). Surgery was performed as described previously
(Kinsey et al., 2009). Briefly, mice were anesthetized with inhaled isoflurane (Phoenix
Pharmaceuticals, Burlingame, CA) with oxygen. The right hind leg was shaved and cleaned with
three alternating wipes of Betadine solution, followed by ethanol. An incision was made on the
skin of the posterior femur. After separating the muscle, the sciatic nerve was isolated and
partially ligated with one 5-0 silk suture that was knotted 4 times. The muscle and skin were then
closed with 6-0 nylon sutures. Mice recovered in clean, heated cages and were observed for
absence of ataxia before being returned to the vivarium. Mice were administered the NSAID
ketoprofen for three days, as a postoperative analgesic.
Behavior assessments. The mice were tested for allodynia, starting one week after
surgery. Mice were tested once a week with a total of 15 testing days. On testing days the mice
were brought into the testing room, weighed, injected, then placed inside ventilated
polycarbonate chambers on an aluminum mesh table and allowed to acclimate for 60 min before
testing. Mice were randomly assigned to drug treatment groups. Mice were injected with
diclofenac sodium or vehicle 60 min before testing. For experiments using JZL184 alone and in
combination with diclofenac, mice were injected with the drug treatment or vehicle 120 min
before testing (Long et al., 2009). The injured paw of the vehicle treated mice acted as the
control. The ipsilateral paw responses from the drug treatment groups were compared to the
ipsilateral vehicle paw responses. The experimenter was blinded to all treatment groups.
Mechanical allodynia. Mechanical allodynia was tested using von Frey filaments (North
Coast Medical, Morgan Hill, CA) using the “up-down” method (Chaplan, Pogrel, & Yaksh,
1994; Kinsey et al., 2009). The plantar surface of each hind paw was stimulated with each
filament, ranging from 0.16-6.0 g, starting with the 0.6 g filament, five times at a frequency of
~2 Hz, (i.e., 2 stimulations per second). The filaments were tested in ascending order until the
mouse lifted its paw after three out of the five stimulations (this was considered to be a positive
response). Once a positive response occurred, the filaments were tested in descending order until
a positive response was not detected, thus establishing a sensory threshold.
Acetone-induced cold allodynia. Approximately 30 min after the von Frey test, 10 µl of
acetone (99% high-performance liquid chromatography grade; Thermo Fisher Scientific,
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Waltham, MA) was propelled via a pipette (USA Scientific, Ocala, FL) onto the plantar surface
of each hind paw to test cold allodynia (Choi, Yoon, Na, Kim, & Chung, 1994; Decosterd &
Woolf, 2000). Acetone was applied from below the testing table via air burst by “expressing” the
pipette, thereby avoiding mechanical stimulation of the paw with the pipette tip. Total time
lifting or clutching each hind paw was recorded with an arbitrary maximum cutoff time of 20 s
(Decosterd & Woolf, 2000).
Drugs. Diclofenac sodium was purchased from Sigma-Aldrich (St. Louis, MO). An
ample stock of JZL184 for the experiments was generously provided on an ongoing basis by our
collaborator, Dr. Anu Mahadevan (Organix, Inc., Woburn, MA). Drugs were dissolved in a
vehicle consisting of ethanol, Cremaphor (Sigma-Aldrich, St. Louis, MO), and normal saline in a
ratio of 1:1:18 (Pinto, Moura, Serrão, Martins, & Vieira-Coelho, 2010). All solutions were
warmed to room temperature and injected intraperitoneally at a volume of 10 µl/g body mass.
Experimental Plan. The first experiment established the dose-response curve for
diclofenac sodium and replicated the published dose-response for JZL184 (Kinsey, Nomura, et
al., 2011) to establish anti-allodynic potency action. Mice were injected intraperitoneally with
vehicle, diclofenac (1, 10, 30, 50, 75, or 100 mg/kg) or JZL184 (1, 4, 8, 16, or 40 mg/kg), and
then assessed for mechanical and cold allodynia.
In the second experiment, a dose-response curve was established for the coadministration
of diclofenac sodium and JZL184. The ED50 values (effective dose at which pain is reduced by
50%) were determined based on the anti-allodynic dose-response curve of each compound from
the first experiment. The ratios of JZL184 and diclofenac sodium are 1:3, 1:1, and 3:1 of the
ED50 of each drug (Naidu et al., 2009). The JZL184 and diclofenac sodium solutions were
equipotent in dose and were determined from the individual dose-responses. The data were
analyzed for subadditive, additive, and synergistic effects using isobolographic analysis.
As the CCI manipulation is a model of chronic pain, it allows for the repeated testing of
mice, following sufficient “wash-out” time (i.e., 7 days between tests). This allows for repeated
testing with no habituation, minimizing the number of animals required to complete these
experiments (Chaplan, Bach, Pogrel, Chung, & Yaksh, 1994).
Inter-rater reliability. All data were collected by a single experimenter. However, prior to
the start of the present study, inter-rater reliability was assessed with two investigators, one with
extensive experience (A) and one with moderate experience (B) for the mechanical allodynia test
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and the cold allodynia test. During the test sessions, the investigators independently assessed
each behavior and recorded responses on separate data sheets for each animal. Data were
analyzed for agreement between investigators using a correlation coefficient. The coefficients for
the investigators were .97 in the mechanical allodynia test and .99 in the cold allodynia test
(Table 1).
Statistical Analysis. The results of the dose response curves of JZL184, diclofenac, and
the combination ratios are presented as means ± S.E.M. Pre- vs. post-surgery paw sensitivity data
were analyzed using a two-way mixed design ANOVA (time point as within subjects and paw as
a between subjects variable) followed by Bonferroni post hoc tests. Dose-response data were
analyzed using one-way ANOVA, followed by Dunnett’s post hoc test.
The ED50 values were calculated using a standard linear regression analysis of the doseresponse curve for each drug or in combination. To determine synergistic, additive, or
subadditive interactions, the theoretical additive ED50 value of the combined drugs were
calculated from the individual dose-response curves. The combination is assumed to equal the
sum of the effects of each drug.
For isobolographic analysis, the dose of diclofenac sodium required to produce a 50%
effect was plotted on the abscissa (x axis) and the isoeffective dose of JZL184 was plotted on the
ordinate (y axis). A straight line connecting the two points represents the theoretical additive
effect of JZL184 and diclofenac sodium. The drugs are considered additive if the experimental
data points and their confidence intervals lie on this line. If the points lie below this line then the
interaction is synergistic. If the points lie above the line the interaction is subadditive (or
antagonistic). The ED50 value of the dual administration was determined by linear regression, in
which the two drugs were summed at each concentration. The statistical difference between the
theoretical ED50 value and the experimental ED50 value was analyzed using a Fisher’s exact test.
Results
CCI induces mechanical and cold allodynia
Mice were tested for allodynia before and one week after CCI surgery. As reported
previously, a significant difference in mechanical [F(1,38) = 93.36, p < .01; Figure 2] and cold
[F(1,38) = 57.42, p < .01] allodynia was observed after the CCI surgery. Post hoc analyses
revealed that this interaction was driven by paws ipsilateral to the nerve injury. On the other
hand, CCI had no effect on paws contralateral to the nerve injury (mechanical allodynia p =.35,
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cold allodynia p = .42). The ipsilateral paws were also significantly different from contralateral
paws (mechanical allodynia p < .01; cold allodynia p < .01) after the CCI surgery.
Either JZL184 or diclofenac sodium dose dependently attenuate allodynia
Both JZL184 and diclofenac sodium dose-dependently attenuated CCI-induced allodynia.
Administration of the MAGL inhibitor JZL184 significantly reduced mechanical allodynia [F (5,
72) = 9.00, p < .01; Figure 3A] and cold allodynia [F (5, 72) = 27.52, p < .01; Figure 3B]. Post
hoc analyses revealed that JZL184 significantly attenuated mechanical allodynia at ≥ 8 mg/kg,
and cold allodynia at ≥ 4 mg/kg. Diclofenac sodium also attenuated mechanical allodynia [F
(6,102) = 4.47, p < .01; Figure 3C] and cold allodynia [F (6,102) = 5.12, p < .01; Figure 3D].
Post hoc analyses revealed that diclofenac significantly attenuated mechanical allodynia at ≥ 50
mg/kg, and cold allodynia at ≥ 75 mg/kg. The ED50 for JZL184 was 8.04 mg/kg (CL 95% =
4.49-14.40 mg/kg) for mechanical allodynia; and 4.13 mg/kg (CL 95% = 3.07-5.56 mg/kg) for
cold allodynia. The ED50 for diclofenac sodium was 76.31 mg/kg (CL 95% = 24.30-239.65
mg/kg) for mechanical allodynia; and 53.50 mg/kg (CL 95% = 21.47-133.31 mg/kg) for cold
allodynia.
Augmented anti-allodynic effects of JZL184 and diclofenac sodium
Coadministration of JZL184 and diclofenac sodium, at low doses, was found to be
synergistically antinociceptive in mechanical allodynia and additive in the cold allodynia test.
Four or five doses of the two compounds were administered in ratios of 1:3, 1:1, or 3:1 parts of
JZL184 and diclofenac. The doses for each of these ratios were determined based on the
respective ED50 value of either compound. The experimentally derived ED50 values (Zmix) from
the dose response curves of the ratios (Figure 4) were compared to the predicted additive ED50
values (Zadd). If the ED50 values of the Zmix are below those of Zadd and the confidence intervals
(CI) do not overlap, then the interaction is considered synergistic. The Zmix in each ratio in the
mechanical allodynia test was significantly less than the Zadd without CI overlap, indicating that
the interaction was synergistic (Table 2). The Zmix in each ratio in the cold allodynia test was
less than the Zadd, however there was some CI overlap, and thus the interaction is considered
additive (Table 2).
The Zmix results from each ratio dose response were plotted on an isobologram and
compared to the predicted values (i.e. theoretical line of additivity) based on the individual ED50
values of either drug. Because the experimental points of the collective mechanical allodynia
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tests lie significantly below the line of additivity, the interaction was synergistic (Figure 5A).
The experimental points of the collective cold allodynia tests do not differ significantly from the
theoretical line of additivity, and thus the interaction was additive (Figure 5B).
Discussion
Traditional pain treatments for neuropathic pain offer inconsistent pain relief and can
have serious side effects including abuse potential, cardiovascular damage, and gastric
hemorrhages, among others. The goal of this study was to test the hypothesis that dual inhibition
of MAGL and COX synergistically decreases nociceptive responses in mice subjected to chronic
constriction injury in mice. First, the analgesic potency of the selective MAGL inhibitor,
JZL184, was tested. The blockade of MAGL with JZL184 dose dependently reduced paw lifts
associated with neuropathic pain, which is consistent with previous findings (e.g. Kinsey et al.,
2009, 2013). MAGL inhibition results in elevated brain and spinal cord levels of 2-AG and
results in analgesia through a CB1 mechanism of action (Long et al., 2009, Kinsey et al., 2009).
MAGL inhibition also has anti-allodynic and anti-edematous properties in an acute inflammation
model (Gosh et al., 2013). In the present study, the blockade of COX via diclofenac reduced
paw lifts at high doses (≥ 50 mg/kg), which is consistent with the literature. However, previous
research has found diclofenac to be effective at doses as low as 30 mg/kg, with the full effect of
COX inhibition being at higher doses (Botting, 2003; Takasaki et al., 2000).
Administration of multiple compounds, especially those in different classes, can increase
analgesic efficacy while also reducing adverse side effects. Combining different drugs into an
effective monotherapy can also simplify prescriptions and increase patient drug compliance
(Raffa, 2001). Dual administration of a FAAH inhibitor and COX inhibitor synergistically
reduces visceral pain, acute inflammation, and thermal and mechanical hyperalgesia in mice
(Naidu et al., 2009; Sasso et al., 2012). In the present study, dual administration of a MAGL
inhibitor and a COX inhibitor reduced mechanical and cold allodynia in a model of neuropathic
pain. Using an isobolographic analysis, a synergistic interaction between diclofenac and JZL184
was found in the mechanical allodynia test and an additive interaction was found in the cold
allodynia test. Thus, dual inhibition of COX and MAGL reduces the dose of either drug to the
extent that significant reductions in allodynia were achieved at subthreshold doses.
Though this study did not directly test the specific mechanism(s) of action of this
interaction, researching the mechanism of this synergistic relationship would be valuable.
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However, because MAGL inhibition decreases brain levels of free arachidonic acid (Nomura
2011) and COX inhibition decreases free arachidonic acid from being converted into
prostaglandins, it is plausible to speculate that both compounds may be working in concert to
alter prostaglandin levels. Alternatively, a possible mechanism for the observed synergistic and
additive interactions is that NSAIDs inhibit COX, thereby decreasing the biosynthesis of
prostaglandins resulting in analgesia (Vane, 1971), while MAGL inhibition increases levels of 2AG acting on CB1 receptors resulting in analgesia (Long et al., 2009). Combining these two
drugs leads to simultaneous reduction of prostaglandin synthesis and activation of CB1 receptors.
Finally, some NSAIDs can inhibit FAAH when given in very high doses, thereby increasing
anandamide brain levels (Holt et al., 2007). However, low doses do not seem to have this same
effect.
Selective COX-2 inhibitors were developed to circumvent the detrimental gastrointestinal
side effects of COX-1 inhibition, however patients using these drugs had a significant increase of
negative cardiovascular events. These results lead to most coxibs, such as Vioxx, being removed
from the market. Non-selective COX inhibitors (i.e. NSAIDs) also have an increased risk of a
cardiovascular event. Cardiovascular risk can increase within a week of treatment initiation,
especially with higher doses (Ong, Ong, Tan, & Chean, 2013). The risk of cardiovascular event
doubled for some NSAIDs at higher doses, while lower doses were nearly risk free for certain
NSAIDs (McGettigan & Henry, 2011). These findings support pain treatment using lower doses
of NSAIDs to avoid adverse side effects.
Inhibition of either FAAH or MAGL prevents the gastrointestinal side effects of highdose NSAID administration (Kinsey, Nomura, et al., 2011; Naidu et al., 2009; Sasso et al.,
2012). The interaction of dual administration of an NSAID and a MAGL inhibitor may further
diminish unwanted NSAID side effects. It is noteworthy that the gastroprotective effects of
MAGL inhibition were not replicated by exogenous administration of the endocannabinoid 2AG, presumably due to its rapid enzymatic regulation in vivo by MAGL, as detailed above
(Kinsey, Nomura, et al., 2011).
Although there are many benefits to endocannabinoid modulation, repeated
administration of high dose JZL184 (≥16 mg/kg) causes downregulation and desensitization of
CB1 receptors. This results in a reversal of the anti-nociceptive and gastroprotective effects of
JZL184. However, repeated administration of low dose JZL184 (e.g., ≤8 mg/kg) did not alter
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receptor expression or function (Kinsey et al., 2013). In other words, at lower doses, repeated
administration of JZL184 maintained previously reported analgesic and gastroprotective effects
(Kinsey et al., 2013). These results support a potential therapeutic treatment of neuropathic pain
with low dose endocannabinoid enzyme inhibitors similar to JZL184.
The ultimate goal of this research is to help identify targets for future pharmacological
therapeutic treatments for patients experiencing neuropathic pain. Thus, a possible future
direction is to examine the effectiveness of a monotherapy using a MAGL inhibitor in clinical
trials in humans. Then, trials using dual administration of an NSAID and a MAGL inhibitor may
be feasible. Although MAGL inhibition has not been tested in humans, a recent clinical trial
tested a FAAH inhibitor in osteoarthritis patients for pain relief. While the drug did inhibit
FAAH activity in the patients, it was indistinguishable from placebo in regard to analgesia
(Huggins, Smart, Langman, Taylor, & Young, 2012). Huggins et al. (2012) speculate that COX
inhibition may also be needed for pain relief in humans. Considering the negative side effects of
COX inhibition via high dose NSAIDs (e.g. gastrointestinal ulcers, cardiovascular, and renal
failure), using a low dose of an NSAID may be ideal, however the lower dose alone might not be
sufficient for analgesia.
More than 12 million people in the United States use prescription drugs non-medically
("Policy impact: Prescription," 2013). This problem is especially rampant in the Appalachian
region. West Virginia has the highest per capita overdose mortality rates in the country and 90%
of these deaths are due to prescription drugs like oxycodone and methadone (Booth &
Kerlikowske, 2001). West Virginia also experienced the biggest increase in unintentional drug
poisoning death rates in the United States (Hall, Hawkinberry, & Moyers-Scott, 2010). Opioid
abuse was the main reason for these deaths, though combining these drugs with alcohol was a
major contributing factor. The direct costs to West Virginia rose to $1.86 billion in 2006 alone
(Hall et al., 2010). Opioid addiction in West Virginia has reached national attention with the
recent documentary “Oxyana,” which details the extensive oxycodone abuse problem in Oceana,
West Virginia. Methadone is another abused opioid that causes death more in patients taking the
prescription for pain relief than those taking methadone for opiate addiction therapy (Paulozzi,
Budnitz, & Xi, 2006). Physicians started prescribing methadone as a pain treatment due to its
lower cost, however the high abuse potential and the depressant effects were initially
underestimated. Recreational use of methadone has increased in recent years. Deaths due to
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methadone in West Virginian were significantly higher in younger age groups than deaths due to
other opioids (Paulozzi et al., 2009). Thus, there is a critical need for new approaches to pain
reduction that have a reduced risk of abuse. Avoiding opioids and other pain treatments that have
high abuse potential would be beneficial to society and for the patient. Endocannabinoid
modulators and NSAIDs both have low abuse liability, which suggests that FAAH or MAGL
inhibitors may indeed make for good treatment options. Dual administration of these drugs along
with an NSAID may further reduce abuse liability.
New pain treatments are also needed because the gastrointestinal side effects of NSAIDs
can be life threatening, especially in elderly patients. Chronic NSAID use in elderly patients has
an increased chance of adverse side effects such as a cardiovascular event and gastric
hemorrhages (Arneric, Laird, Chappell, & Kennedy, 2013; Ong et al., 2013). Older people are
among the highest users of analgesic medications (Arneric et al., 2013), however there has not
been sufficient research to determine the safest treatment options for these patients. For example,
there have been few clinical trials specifically investigating elderly patients, due to cognitive and
health exclusion criteria. However the co-morbidities that are associated with the elderly may
have an impact on the efficacy and safety of these analgesics (Arneric et al., 2013) If pain is not
managed effectively it can lead to loss of mobility, physical function, and a decrease in the
quality of life for older patients.
Possible future directions of this research include testing dual administration of the
MAGL inhibitor and an NSAID in other models of pain, such as inflammatory or postsurgical
hyperalgesia. Because dual administration of these two classes of drugs yield significant
analgesic potency at low doses, this strategy may not just be limited to neuropathic pain but may
instead be used effectively in a myriad of ailments. For example, as mentioned above, dual
FAAH/COX inhibition reduces acute visceral pain (Naidu et al., 2009), although MAGL
inhibitors have not been tested in this paradigm. Similarly, although it has been reported
previously that chronic low dose JZL184 does not cause functional CB1 receptor loss (Kinsey et
al., 2013), it is possible that chronic dual administration could have unknown negative effects
that may or may not be limited to CB1. Thus, a longer-term study in which JZL184 and
diclofenac are administered repeatedly may be worth investigating.
One limitation of the present study is that it did not investigate the possible analgesic
effects of JZL184 and/or diclofenac on spontaneous pain. Spontaneous pain, which includes
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phantom limb pain, is a common type of chronic pain that results from neuropathy in humans.
Unfortunately, there are no well-accepted preclinical animal models of spontaneous pain, and so
interpretation of the present data is limited to neuropathic allodynia. That is, the analgesic effects
of COX and MAGL inhibition may or may not effectively treat spontaneous pain. It may well be
the case that little will be known about the analgesic efficacy of endocannabinoid modulation in
spontaneous pain until clinical trials are conducted in neuropathic pain patients. While other
types of chronic pain are more common, patients with neuropathic pain tend to report higher pain
severity scores and an increase use of analgesics (Torrance, Smith, Bennett, & Lee, 2006), again
underscoring the need to develop new effective pain treatments.
In summary, coadministration of JZL184 and diclofenac sodium synergistically reduced
CCI-induced mechanical allodynia and additively reduced cold allodynia in mice. The combined
inhibition of MAGL and COX enzymes may be beneficial in maximizing analgesia while at the
same time reducing NSAID side effects, in particular gastrointestinal ulcers. While this is an
exciting outcome, MAGL inhibitors are not currently approved for use in humans, and thus
clinical trials are still needed to test the efficacy of these drugs. In addition, further research is
needed to elucidate the specific physiological mechanisms by which the observed synergistic
reduction in allodynia occurs.
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Table 1
P values for inter-observer correlation
Mechanical Allodynia Correlation

Investigator A

Investigator B

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

Investigator A

Investigator B

1

.973**
.000
24
1

24
.973**
.000
24

24

Cold Allodynia Correlation
Investigator A
Investigator A

Pearson Correlation
1
Sig. (2-tailed)
N
24
Investigator B
Pearson Correlation
.989**
Sig. (2-tailed)
.000
N
24
** Correlation is significant at the .01 level (2-tailed)

Investigator B
.989**
.000
24
1
24

Table 1. Prior to the start of the present study, inter-rater reliability was assessed with two
investigators, one with extensive experience (A) and one with moderate experience (B) in testing
using the “up-down” method in the mechanical allodynia test and using separate stop watches in
the cold allodynia test. During the test sessions the investigators recorded responses on separate
data sheets for each animal. Data were analyzed for agreement between investigators using
Pearson correlation, ** p < .01.
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Table 2
ED50 values of JZL184 and diclofenac sodium in combination

Combination
(doses in mg/kg)

ED50 mg/kg ip (95% Confidence
Limit) JZL184:Diclofenac

Combination
Ratio

JZL184:Diclofenac
.5:5.5
1:11
2:22
4:44
8:88

1:1

JZL184:Diclofenac
.5:1.85
1:3.7
2:7.4
4:14.8
8:29.6

3:1

JZL184:Diclofenac
.5:16.5
1:33
2:66
4:132

1:3

Zadd
(Theoretical)
35.99 (26.4645.53)

Zmix
(Experimental)
8.85 (5.0915.40)*

Cold Allodynia

29.03 (11.1540.19)

22.88 (14.6035.85)

Mechanical
Allodynia

21.41 (16.3126.51)

4.68 (3.14-6.96)*

Cold Allodynia

16.94 (12.4129.35)

Mechanical
Allodynia

50.58 (36.3964.76)

Mechanical
Allodynia

10.24 (6.5516.02)

19.48 (11.3033.56)*

Cold Allodynia

41.12 (27.7430.59 (21.7068.86)
43.13)
The Zadd and Zmix values reflect the total amount of both drugs combined, where diclofenac and
JZL184 were summed for each combination.
* p < .05 compared with Zadd using the Fisher test.
Experimentally determined Zmix values and predicted Zadd values (95% CL) for mixtures of
JZL184 and diclofenac in assays of acetone and von Frey. Asterisks indicate a synergistic
interaction as evidence of non-overlapping 95% CL between Zmix and Zadd values.
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Figure 1. Schematic drawing of the endocannabinoid (eCB) system. The two eCB receptors bind
the endocannabinoids anandamide and 2-AG. These endocannabinoids are tightly regulated by
the metabolic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase
(MAGL). Pharmacological inhibition of FAAH or MAGL causes an increase in physiological
levels of the eCB that either enzyme metabolizes. For example, the compound JZL184 inhibits
MAGL activity, which indirectly increases brain levels of the endocannabinoid 2-AG. Red
arrows indicate decreased function, green arrow indicate increased function
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Figure 2. Chronic constriction injury causes mechanical and cold allodynia. Mice were tested for
(A) mechanical and (B) cold allodynia prior to and one week following surgery. Data are
expressed as mean (±) SEM. (n = 20). ** p < .01 versus contralateral paw, ## p <.01 versus presurgery ipsilateral paw, Bonferroni post hoc.
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Figure 3. The MAGL inhibitor, JZL184, or the COX inhibitor, diclofenac sodium, dose-dependently attenuates
mechanical and cold allodynia in the CCI model of neuropathic pain. Mice were subjected to CCI and then
tested for mechanical (A, B) and acetone-induced cold allodynia (C, D). Data are expressed as mean (±) SEM.
(n = 10-18). ** p < .01 versus vehicle, Dunnett post hoc.
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Figure 4. Dual administration of JZL184 and diclofenac attenuates mechanical and cold allodynia. Ratios of
1:1, 3:1, and 1:3 (JZL184:diclofenac) were administered 120 min prior to testing. Data are expressed as mean
(±) SEM. (n = 10). * p < .05 versus vehicle, ** p < .01 versus vehicle, Dunnett post hoc.
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Figure 5. Coadministration of JZL184 and diclofenac sodium elicits synergistic analgesia in the mechanical
allodynia test and additive analgesia in the cold allodynia test. Isobologram of the interactions between JZL184
and diclofenac in the CCI-induced allodynia model. The ED50 values for JZL184 and diclofenac are depicted on
the x and y axes, respectively. The isobole of additivity is shown as a solid line connecting the ED50 values of
JZL184 and diclofenac and depicting the theoretical line of additivity. The experimental ED50 values with 95%
confidence interval of mixtures of JZL184 and diclofenac at fixed-ratio combinations of 1:1, 3:1, and 1:3 were
significantly below the theoretical isoboles of additivity in the mechanical allodynia test, indication of a
synergistic interaction. The experimental ED50 values in the cold allodynia test do not differ significantly than
the theoretical isobole, and thus the interaction is considered additive. * p < .05 (n = 10 mice/treatment group).

